Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
Transplantation and Cellular Therapy · 2023-03 · 29 (3) · 181.e1-181.e10
DOI: 10.1016/j.jtct.2022.12.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation and Cellular Therapy, 2023-03. Verfasst von Alexandra Pedraza und 15 weiteren Autor:innen. Beteiligte Einrichtung: Blood Bank Department, Hematopoietic Transplantation Unit, Banc de Sang i Teixits, Hospital Clínic, Barcelona, Spain. Electronic address: acpedraza@c…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The impact of infused CD34+ cell dose on outcomes after allogeneic hematopoietic stem cell transplantation (alloHSCT) using standard graft-versus-host disease (GVHD) prophylaxis remains controversial. Information on this subject is scarce for alloHSCT using high-dose post-transplantation cyclophosphamide (PTCy). We aimed to assess the effect of CD34+ cell dose in peripheral blood stem cell (PBSC) grafts on the outcome of alloHSCT using PTCy-based GVHD prophylaxis. To do so, we conducted a single-center retrospective analysis of 221 consecutive adult patients who underwent PTCy alloHSCT from HLA-matched sibling donors (MSDs; n = 22), HLA-matched unrelated donors (MUDs; n = 83), mismatched unrelated donors (MMUDs; n = 73), and haploidentical donors (n = 43). Based on the binary partitioning method, 5 × 106/kg was used as the optimal cutoff for CD34+ cell dose. According to our institutional protocol, the maximum CD34+ cell dose was capped at 8 × 106/kg. The study cohort was divided into 2 groups based on CD34+ cell dose: high dose (>5 to 8 × 106/kg) and low dose (≤5 × 106/kg). Patients receiving high-dose CD34+-containing grafts had significantly shorter median times to neutrophil engraftment and platelet engraftment compared to those who received low-dose CD34+ (19 days versus 21 days [P = .002] and 16 days versus 22 days [P = .04], respectively). There were no differences between the high-dose and low-dose groups in the cumulative incidence of day +100 acute GVHD (grade II-IV: 25% versus 23% [P = .7]; grade III-IV: 5% versus 4% [P = .4], respectively) or 2-year chronic GVHD (moderate/severe GVHD: 9% versus 6%; P = .5). There was no impact of CD34+ cell dose on survival outcomes with the use of MSDs, MUDs, or MMUDs. Recipients of haploidentical alloHSCT using low-dose CD34+ cells had significantly worse overall survival (hazard ratio [HR], 6.01; P = .004) and relapse-free survival (HR, 4.57; P = .004). In recipients of PBSC PTCy alloHSCT, infused CD34+ cell doses >5 to 8 × 106/kg were associated with faster neutrophil and platelet engraftment, independent of donor type. Our study suggests an impact of CD34+ cell dose on survival outcomes only with haploidentical donors, for whom the administration of a CD34+ cell dose ≤5 × 106/kg significantly decreased survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blood Bank Department, Hematopoietic Transplantation Unit, Banc de Sang i Teixits, Hospital Clínic, Barcelona, Spain. Electronic address: acpedraza@clinic.cat.
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, Barcelona, Spain.
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, Barcelona, Spain; August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, Barcelona, Spain; August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Institute…
Zitieren
APA
Pedraza, A., Salas, M. Q., Rodríguez-Lobato, L. G., Charry, P., Suárez-Lledo, M., Martínez-Cibrian, N., Doménech, A., Solano, M. T., Arcarons, J., de Llobet, N., Rosiñol, L., Gutiérrez-García, G., Avilés, F. F., Urbano-Ispízua, Á., Rovira, M., & Martínez, C. (2023). Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 29(3), 181.e1-181.e10. https://doi.org/10.1016/j.jtct.2022.12.005
Vancouver
Pedraza A, Salas MQ, Rodríguez-Lobato LG, Charry P, Suárez-Lledo M, Martínez-Cibrian N, et al. Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. 2023;29(3):181.e1-181.e10. doi:10.1016/j.jtct.2022.12.005
BibTeX
@article{Pedraza2023,
author = {Pedraza, Alexandra and Salas, María Queralt and Rodríguez-Lobato, Luis Gerardo and Charry, Paola and Suárez-Lledo, María and Martínez-Cibrian, Nuria and Doménech, Ariadna and Solano, Maria Teresa and Arcarons, Jordi and de Llobet, Noemí and Rosiñol, Laura and Gutiérrez-García, Gonzalo and Avilés, Francesc Fernández and Urbano-Ispízua, Álvaro and Rovira, Montserrat and Martínez, Carmen},
title = {Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide},
journal = {Transplantation and Cellular Therapy},
year = {2023},
volume = {29},
number = {3},
pages = {181.e1--181.e10},
doi = {10.1016/j.jtct.2022.12.005}
}
EUVIMED